Altimmune Stock Analysis


USD 12.00  1.00  7.69%   

The modest gains experienced by current holders of Altimmune could raise concerns from private investors as the firm is trading at a share price of 12.00 on very low momentum in volume. The company executives have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.89. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Altimmune partners.
Please continue to Trending Equities.
The Altimmune stock analysis report makes it easy to digest most publicly released information about Altimmune and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Altimmune Stock analysis module also helps to analyze the Altimmune price relationship with some important fundamental indicators such as market cap and management efficiency.

Altimmune Stock Analysis Notes

About 86.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.96. Some equities with similar Price to Book (P/B) outperform the market in the long run. Altimmune recorded a loss per share of 1.91. The entity last dividend was issued on the 20th of January 2017. The firm had a split on the 14th of September 2018. Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Altimmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 47 people. For more info on Altimmune please contact William Enright at 240 654 1450 or go to

Altimmune Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Altimmune's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Altimmune or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Altimmune has very high historical volatility over the last 90 days
The company reported the last year's revenue of 3.6 M. Reported Net Loss for the year was (101.66 M) with loss before taxes, overhead, and interest of (71.09 M).
Altimmune has about 179.95 M in cash with (72.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.19.
Over 86.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Payment of 3008 shares by Vipin Garg of Altimmune subject to Rule 16b-3

Altimmune Upcoming and Recent Events

Earnings reports are used by Altimmune to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Altimmune previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report16th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Altimmune SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Altimmune prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Altimmune investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Altimmune specific information freely available to individual and institutional investors to make a timely investment decision.
14th of September 2022
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
11th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
8th of July 2022
Unclassified Corporate Event
7th of July 2022
Unclassified Corporate Event
12th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
11th of April 2022
Unclassified Corporate Event
24th of March 2022
Unclassified Corporate Event
15th of March 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition

Altimmune Thematic Classifications

In addition to having Altimmune stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotechnology and pharmaceuticals production and services

Altimmune Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Altimmune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Altimmune backward and forwards among themselves. Altimmune's institutional investor refers to the entity that pools money to purchase Altimmune's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Tang Capital Management LlcCommon Shares3.6 M42.1 M
Nuveen Asset Management LlcCommon Shares3.1 M35.9 M
Cormorant Asset Management LpCommon SharesM35.1 M
Avidity Partners Management LpCommon SharesM34.9 M
Baker Bros Advisors LpCommon Shares2.1 M24.3 M
Vanguard Group IncCommon Shares1.7 M20.2 M
Sphera Funds Management LtdCommon Shares1.4 M16.3 M
Note, although Altimmune's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Altimmune Market Capitalization

The company currently falls under 'Small-Cap' category with total capitalization of 476.86 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Altimmune's market, we take the total number of its shares issued and multiply it by Altimmune's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has Return on Asset of (24.51) % which means that on every $100 spent on asset, it lost $24.51. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (47.14) %, meaning that it generated no profit with money invested by stockholders. Altimmune management efficiency ratios could be used to measure how well altimmune manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 6th of October, Altimmune shows the Downside Deviation of 6.74, risk adjusted performance of 0.0454, and Mean Deviation of 4.51. Altimmune technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Altimmune, which can be compared to its rivals. Please confirm Altimmune variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Altimmune is priced correctly, providing market reflects its regular price of 12.0 per share. Given that Altimmune has jensen alpha of 0.2354, we suggest you to validate Altimmune's prevailing market performance to make sure the company can sustain itself at a future point.

Altimmune Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to Altimmune price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator.

Altimmune Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Altimmune insiders, such as employees or executives, is commonly permitted as long as it does not rely on Altimmune's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Altimmune insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Altimmune Technical and Predictive Indicators

Altimmune Forecast Models

Altimmune time-series forecasting models is one of many Altimmune's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Altimmune's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Altimmune Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Altimmune prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Altimmune shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Altimmune. By using and applying Altimmune Stock analysis, traders can create a robust methodology for identifying Altimmune entry and exit points for their positions.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Altimmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 47 people.

Current Altimmune Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Altimmune analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Altimmune analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
30.5Strong Buy6Odds
Altimmune current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Altimmune analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Altimmune stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Altimmune, talking to its executives and customers, or listening to Altimmune conference calls.
Altimmune Analyst Advice Details

Altimmune Stock Analysis Indicators

Altimmune stock analysis indicators help investors evaluate how Altimmune stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Altimmune shares will generate the highest return on investment. By understating and applying Altimmune stock analysis, traders can identify Altimmune position entry and exit signals to maximize returns.
Quick Ratio9.73
Fifty Two Week Low3.83
Revenue Growth-96.20%
Shares Short Prior Month6.16M
Average Daily Volume Last 10 Day1.87M
Average Daily Volume In Three Month2.49M
Shares Percent Shares Out10.18%
Short Percent Of Float11.46%
Forward Price Earnings-5.29
Float Shares32.13M
Fifty Two Week High23.49
Enterprise Value To Ebitda-3.68
Fifty Day Average15.59
Two Hundred Day Average9.50
Enterprise Value To Revenue93.46
Please continue to Trending Equities. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for analysis

When running Altimmune price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
CEO Directory
Screen CEOs from public companies around the world
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine Altimmune value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.